THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

Q-LINE BIOTECH LIMITED

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE")

Our Company was originally incorporated as "POCT Services Private Limited" on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited'', and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled "History and Corporate Structure" beginning on page 152 of the Prospectus.

a) Any disruption, stoppage, slowdown or shutdown in our manufacturing facilities or process or research and development activities could adversely affect our business, financial condition, cash flows and results of operations.

b) Any delay, interruption or reduction in the supply of our raw materials, trade goods from our suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of our products and have an adverse effect on our business, financial condition, cash flows and results of operations.

c) Our business is dependent on the sale of our products through distributors which also include our group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of our products and could negatively impact our business, results of operations, financial conditions and cash flows.

d) We are dependent on certain key suppliers to procure a significant portion of our Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in our operations, which could have an adverse effect on our business, financial condition, results of operations and cash flows.

e) We are required to obtain, maintain or renew our statutory and regulatory approvals, licenses, and registrations to operate our business.

f) For manufacturing of our machines and reagents, we are dependent on the agreement with the European companies, any failure to renew the agreement or entering into the agreement on the terms which are not favourable for us may impact our business operations, financial condition and cash flows.

g) Our erstwhile associate company i.e. POCT Science House Private Limited and our promoters namely Saurabh Garg and Amita Garg have been subject to search and seizure operations by the Income-tax Department and any adverse outcome of these proceedings may adversely affect our financial condition.

h) Our operations are concentrated in North India, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.

i) Our Company requires a significant amount of working capital for continuing growth. Our inability to meet our working capital requirements may adversely affect our results of operations.

j) We are subject to risks arising from exchange rate fluctuations.

k) The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issues were closed below the Issue Price on listing date:

*Issue in which both BRLMs were involved.

1) Average cost of acquisition of Equity Shares held by the Promoters is

m) The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end (Rs. 343) of the Price Band is 11.98

n) Weighted Average Return on Net worth for Fiscals 2025, 2024 and 2023 is 23.17%.

o) The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

p) The Weighted average cost of acquisition compared to Floor Price and Cap Price.

^^There were no secondary transactions in last 18 months from the date of the Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transaction").

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), 40% of the Anchor Investor Portion shall be reserved for, (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price. In the event of under- proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-lnstitutional Bidders (1/3rd of the subscription in (ii) above, the allocation may be made to domestic Mutual Funds in accordance with the SEBI ICDR Regulations. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate portion available to NIBs shall be reserved for applicants with an application size of more than 2 lots and upto such lots equivalent to not more than Rs. 10.00 Lakhs and 2/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than Rs. 10.00 Lakhs and the unsubscribed portion in either of the sub categories, could be allocated to applicants in the other sub-category of NIBs) and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Investors using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 341 of the Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on May 29, 2026*

*Subject to the receipt of listing and trading approval from the NSE (''NSE EMERGE").

The bidding for Anchor Investors opened and closed on Wednesday, May 20, 2026. The Company received 18 Anchor Investors applications for 20,43,600 Equity Shares. The Anchor Investor Allocation price was finalized at Rs. 343/- per Equity Share. A total of 17,81,200 Equity Shares were allotted under the Anchor Investors portion aggregating to Rs. 61,09,51,600.00

The Issue (excluding Anchor Investors Portion) received 2,36,894 Applications for 42,80,91,600 Equity Shares (after considering invalid bids, Other than RC10 Transaction declined by Investors, RC10 Mandate not accepted by Investors and Withdrawal/ Cancelled Bids reported by SCSB and rejections) resulting 95.73 times subscription (including reserved portion of market maker and excluding anchor investor portion). The details of the Applications received in the Issue from various categories are as under (before rejections):

Detail of the Applications Received (excluding Anchor Investors Portion):

A summary of the final demand as per NSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

The Basis of Allotment was finalized in consultation with the designated Stock Exchange, being National Stock Exchange of India Limited ("NSE EMERGE") on May 26, 2026.

1. Allotment to Individual Investors (After Rejections):

The Basis of Allotment to the Individual Investors, who have Bid at or above the Issue Price of Rs. 343/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 70.27 times i.e. for 14,61,12,800 Equity Shares. The total number of Equity Shares Allotted in this category is 20,79,200 Equity to 2,599 successful applicants. The details of the Basis of Allotment of the said category are as under:

2. Allotment to Non-lnstitutional Investors (More than 2 lots and up to Rs. 10,00,000) (After Rejections):

The Basis of Allotment to the Non-lnstitutional Investors, who have bid at the Issue Price of Rs. 343/- or above per Equity Share was finalized in consultation with NSE. The category has been subscribed to the extent of 80.67 times i.e. for 2,39,74,800 Equity Shares (after rejection). The total number of Equity Shares Allotted in this category is 2,97,200 Equity Shares to 247 successful applicants. The details of the Basis of Allotment of the said category are as under:

3. Allotment to Non-Institutional Investors (More than Rs. 10,00,000)

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of Rs. 343/- or above per Equity Share was finalized in consultation with NSE. The category has been subscribed to the extent of 178.11 times i.e. for 10,58,66,000 Equity Shares (after rejection). The total number of Equity Shares Allotted in this category is 5,94,400 Equity to 495 successful applicants. The details of the Basis of Allotment of the said category are as under:

4. Allotment to Market Maker: The Basis of Allotment to Market Maker who have bid at Issue Price of Rs. 343/- per Equity Shares or above, was finalized in consultation with NSE. The category was subscribed by 1.00 times i.e. for 3,13,200 Equity shares the total number of shares allotted in this category is 3,13,200 Equity Shares. The category wise details of the Basis of Allotment are as under:

5. Allotment to QIBs excluding Anchor Investors (After Rejections):

The Basis of Allotment to QIBs, who have bid at Issue Price of Rs. 343/- per Equity Shares or above, was finalized in consultation with MSE. The category was subscribed by 123.80 times i.e. for 14,70,73,200 Equity shares. As per the SEBI Regulations. 5% of Met QIB portion was reserved for mutual funds i.e. 59,200 Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were allotted the remaining available Equity Shares i.e. 11,28,800 Equity Shares on a proportionate basis. The total number of shares allotted in this category is 11,88,000 Equity Shares to 115 successful applicants. The category wise details of the Basis of Allotment are as under:

6. Allotment to Anchor Investors (After Rejections):

The Company in consultation with the BRLM has allocated 17,81,200 Equity Shares to 18 Anchor Investors at the Anchor Investor Issue Price of Rs. 343/- per Equity Shares in accordance with the SEBI (ICDR) Regulations. This represents upto 60% of the QIB Category.

The Board of Directors of our Company at its meeting held on May 26, 2026 has taken on record the basis of allotment of Equity Shares approved by the designated Stock Exchange, being NSE and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched / mailed for unblocking of funds and transfer to the Public Issue Account on or before May 27, 2026. In case the same is not received within ten days, Investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on May 27, 2026 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from NSE and the trading of the Equity Shares is expected to commence trading on May 29, 2026.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated May 26, 2026 filed with the Registrar of Companies, Uttar Pradesh I ("RoC").

TRACK RECORD OF BOOK RUNNING LEAD MANAGER: The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issues were closed below the Issue Price on listing date:

*Issue in which both BRLMs were involved.

Al future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole Bidder Serial number of the ASBA form, number of Equity Shares bid for, Bidder DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designate Intermediary where the Bid cum Application Form was submitted by the Bidder and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:

	Purva Sharegistry (India) Private Limited
	Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011
	Tel. No.: 91 22 41343255/41343271
	Email: newissue@purvashare.com
	Website: www.purvashare.com
	Contact Person: Deepali Gaonkar
	SEBI Registration No.: INR000001112